A phase III development program of ALLN-177

Trial Profile

A phase III development program of ALLN-177

Phase of Trial: Phase III

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs ALLN 177 (Primary)
  • Indications Hyperoxaluria
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2016 New trial record
    • 10 Feb 2016 This trial is expected to begin in 2017, according to an Allena Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top